Inoviq Ltd · ASX:IIQ
Inoviq — ShareCafe Small Cap Sip and Learn Webinar (Hidden Gems Webinar) 2025
24 slides from Inoviq's conference presentation, Mar 19, 2025
Slide 1: INOVIQ Investor Webinar Presentation
ASX Announcement 19 March 2025 INOVIQ INVESTOR WEBINAR PRESENTATION Melbourne, Australia, 19 March 2025: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) advises that CEO Dr Leearne Hinch will be presenting in the ShareCafe Small Cap “Sip and Learn” Webinar on the 19 March 2025. The details and link
Slide 2: INOVIQ overview: Next-generation cancer diagnostics and therapeutics
INOVIQ overview For personal use only Next-generation cancer diagnostics and therapeutics Hidden Gems Webinar 19th March 2025 ASX: IIQ
Slide 3: Important notice and disclaimer
Important notice and disclaimer For personal use only This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. Th
Slide 4: INOVIQ Overview: Next generation diagnostics and therapeutics
INOVIQ Overview| Next generation diagnostics and therapeutics For personal use only Exosome Disruptive Products powered technology in market • Biotech pioneering next-generation cancer diagnostics and therapeutics to enhance patient outcomes Next-gen exosome Patented exosome Exosome research tools s
Slide 5: Vision: Leading exosome diagnostics and therapeutics company
Vision| Leading exosome diagnostics and therapeutics company For personal use only Strategic Focus Core Technologies Exosome Platform SubB2M Technology Next-generation exosome diagnostics and therapeutics NETs immunoaffinity, magnetic Proprietary neu5Gc probe for bead-based EV isolation for cancer i
Slide 6: Products & pipeline: Multi-stage diagnostics and therapeutics portfolio
Products & pipeline| Multi-stage diagnostics and therapeutics portfolio For personal use only Product Indication and Use Development Stage Next Milestones (CY) Market Opportunity Biomarker Discovery & Diagnostics In-Market Sales Growth & EXO-NET Pan EV Capture RUO Collaborations Neurology Diagnostic
Slide 7: Exosomes: Significant diagnostic and therapeutic potential
Exosomes| Significant diagnostic and therapeutic potential For personal use only • Exosomes are small vesicles released by cells that perform key roles in intercellular communication, immune regulation and disease progression DNA ➢ Exosomes carry molecular cargo (DNA, RNA, proteins and lipids) that
Slide 8: EXO-NET: Pan-exosome isolation product in-market
EXO-NET®| Pan-exosome isolation product in-market and generating revenue For personal use only Best-in-class EXO-NET pan-exosome capture tool (research use only) in-market and surface generating revenue antigens Enables biomarker discovery and diagnostic development for screening, liquid biopsies an
Slide 9: NEURO-NET: Brain-derived exosome isolation validated & available
NEURO-NET | Brain-derived exosome isolation validated & available For personal use only Custom NEURO-NET exosome capture tool for isolation of brain-derived exosomes NEURO-NET identifies NEURO-NET identifies known Alzheimer’s differently-expressed proteinsdisease from Designed using proprietary anti
Slide 10: EXO-NET Distribution: Promega Corporation
EXO-NET Distribution| Promega Corporation For personal use only • EXO-NET customers: as at 13th Feb-25 Customer Profile # • 51 total customers: won in 6.5 months since Aug-24 (> 8/mo) type from EU, US and Asia Academic/ Exosome KOLs validating EXO-NET 21 • Applications: Oncology, Neurology, Cardiac
Slide 11: Exosome Diagnostics: Academic collaboration validating EXO-NET
Exosome Diagnostics| Academic collaboration validating EXO-NET For personal use only Collaboration with UQ to develop blood-based exosomal screening test for ovarian cancer1 ROC analysis of EXO-OC in independent sample set • UQ1 OCRF-7 test developed in a 465-sample retrospective case-control study
Slide 12: Ovarian Cancer screening test: Path-to-market
Ovarian Cancer screening test| Path-to-market For personal use only • #8 cancer in women & deadliest gynaecological cancer • 314k new cases of ovarian cancer worldwide pa1 Development Path Ovarian Cancer • 0.25% of population has Hereditary Breast and Ovarian Cancer syndrome2 Feasibility Completed •
Slide 13: Exosome Therapeutics: Next-gen cell-free therapy
Exosome Therapeutics| Next-gen cell-free therapy For personal use only • INOVIQ is developing weaponised exosomes engineered to Second-line tx Blood cancers CAR-exosome target and kill solid tumours Next-gen cell-free therapy Standalone or combination Follow-on to autologous therapy CAR-T therapy •
Slide 14: CAR-Exosomes: Allogenic EV-based therapy with multiple advantages
CAR-Exosomes| Allogenic EV-based therapy with multiple advantages For personal use only Engineer Establish In vivo Activate and In vitro Phase I/II immortalized Master Cell Isolate EVs animal IND expand efficacy Clinical Trials CAR-cells Bank studies ✓ Improved safety profile due to reduced GvHD (im
Slide 15: CAR-Exosomes: Target and kill cancer cells
CAR-Exosomes| Target and kill cancer cells For personal use only CAR-EVs inherit the targeting and cytotoxic properties of their parent CAR-T or CAR-NK cells • CAR-EVs are produced by CAR-T/NK cells • CAR-EVs contains catalytic proteins (perforin and granzyme B) • CAR-EVs interact and internalise in
Slide 16: CAR-Exosomes: Development path
CAR-Exosomes| Development path For personal use only EXO-ACE In Vivo Selection First Patient CAR EV Isolation Studies of CRO Dose CAR-T / NK Cell In Vitro IND Regulatory Approval Development Studies Submission and Site Selection ✓Master cell ✓High purity & ✓In vitro PoC for • In vivo studies banks y
Slide 17: SubB2M Diagnostics: Glycan-binding technology and scientific rationale
SubB2M Diagnostics| Glycan-binding technology and scientific rationale For personal use only Aberrant glycosylation (production of sugars) is a hallmark of cancer Neu5Gc is a sugar commonly found on cancer cells, but not healthy cells SubB2M is an engineered protein that specifically binds neu5Gc Su
Slide 18: Breast Cancer monitoring test: Path-to-market
Breast Cancer monitoring test| Path-to-market For personal use only • #1 cancer in women Development Path Breast Cancer • 2.3m new cases of breast cancer worldwide pa1 • 7.8m survivors (5-year)1 Feasibility Completed • Non-invasive, earlier and more accurate tests required for monitoring breast Unme
Slide 19: SubB2M Breast Cancer clinical data: Outperformed leading CA15-3 test
SubB2M Breast Cancer clinical data| Outperformed leading CA15-3 test For personal use only Clinical Validation Study by Stage (2023)1 SubB2M CA15-3 vs Leading Existing Test Retrospective, case-control, clinical validation study (n=483) to Breast Cancer SubB2M Roche evaluate breast cancer detection b
Slide 20: Summary: Positioned for growth
Summary| Positioned for growth For personal use only Financial information (ASX:IIQ) Ordinary shares1 111,526,702 Proprietary exosome platform with multiple research, diagnostic and therapeutic applications Listed / Unlisted options1 9,753,913 / 8,791,667 52-week H/L1 A$0.80-0.345 Global distributio
Slide 21: Future catalysts: Developing better healthcare solutions
For personal use only Future catalysts| Developing better healthcare solutions EXO Research Tools TEXO-NET validation data Exosome Program Commence EXO-OC test EXO-OC test biomarker EXO-Dx-OC clinical validation for validation data ovarian cancer screening Commence exosome EXO-Dx- Exosome diagnostic
Slide 22: Contacts
Contacts For personal use only Dr Leearne Hinch BVMS MBA Chief Executive Officer e. lhinch@inoviq.com INOVIQ Ltd, 23 Normanby Road, Notting Hill, VIC 3168 Australia 21 p. +61 3 9548 7586 | e. info@inoviq.com | w. www.inoviq.com
Slide 23: Board & Management: Corporate, scientific and commercial expertise
Board & Management| Corporate, scientific and commercial expertise For personal use only DAVID WILLIAMS DR GEOFF CUMMING MAX JOHNSTON PHILIP POWELL MARY HARNEY Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Experienced biotechnology
Slide 24: Advisory Board: Renowned clinical researchers and oncologists
Advisory Board| Renowned clinical researchers and oncologists For personal use only PROF MILES PRINCE AM PROF PHIL DARCY PROF CARLOS SALOMON DR JAMES MCCRACKEN Clinical Haematologist & Principal Research Fellow NHMRC Investigator Fellow Medical Oncologist Oncologist Leading Clinical Haematologist an
INOVIQ — ShareCafe Small Cap Sip and Learn Webinar (Hidden Gems Webinar) 2025 on 6ix